# Early Prediction of Therapeutic Response to Targeted Therapy in Stage IIIB/IV or Recurrent Lung Cancer Patients

> **NCT00708448** · PHASE1 · COMPLETED · sponsor: **University of Utah** · enrollment: 26 (actual)

## Conditions studied

- Cancer
- Non Small Cell Lung Cancer

## Interventions

- **RADIATION:** PET Imaging
- **DRUG:** Erlotinib
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT00708448
- **Lead sponsor:** University of Utah
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-03-28
- **Primary completion:** 2010-08-12
- **Final completion:** 2010-08-12
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2025-02-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00708448

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00708448, "Early Prediction of Therapeutic Response to Targeted Therapy in Stage IIIB/IV or Recurrent Lung Cancer Patients". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT00708448. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*